Breathe Well Live Well
|
Dust Mite SLIT Promising Add-On to Asthma Maintenance Meds
MedPage Today Adding dust mite sublingual allergen immunotherapy (SLIT) to maintenance asthma medications significantly prolonged the time to a first asthma exacerbation during planned inhaled corticosteroid reduction, but mild to moderate adverse events were … |
View full post on asthma – Google News
|
SPIRIVA® RESPIMAT® Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Business Wire (press release) INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a … |
View full post on asthma – Google News
|
SPIRIVA ® RESPIMAT ® Now Available in the US for Maintenance Treatment of Asthma in Adults and Adolescents
Business Wire (press release) INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a … SPIRIVA RESPIMAT Now Available in the US for Maintenance Treatment of Asthma in Adults and Adolescents |
View full post on asthma – Google News
|
SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
PR Newswire (press release) RIDGEFIELD, Conn., Feb. 3, 2016 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma in U.S. pharmacies. The U.S. Food and Drug … |
View full post on asthma – Google News
|
First-in-class biologic maintenance therapy approved for severe asthma
ModernMedicine Nucala, developed by GlaxoSmithKline, is an interleukin-5 (IL-5) antagonist monoclonal antibody that reduces the production and survival of esosinophils, which are one of the inflammatory cell types involved in asthma. The biologic is to be … |
View full post on asthma – Google News
Ledger Gazette |
FDA approves Mepolizumab for maintenance treatment of severe asthma
Ledger Gazette The US Food and Drug Administration has cleared use of Nucala (mepolizumab) in patients with severe asthma aged 12 years and older whose condition is driven by eosinophilic inflammation, offering patients access to the first and only approved biologic … Nucala approved to treat severe asthma |
View full post on asthma – Google News
|
GSK's Nucala gets FDA nod in asthma maintenance
BioWorld Online The FDA added another drug to the asthma armamentarium, with the approval of Glaxosmithkline plc's Nucala (mepolizumab) as a maintenance therapy for patients who have a history of severe asthma attacks despite being on treatment. Approval, disclosed … |
View full post on asthma – Google News
|
FDA expands indication of BI inhaler to include maintenance treatment of asthma
FierceDrugDelivery The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD. The expanded indication … FDA Approves New Indication for Boehringer's Spiriva Respimat Landmark year for Boehringer Ingelheim's respiratory portfolio – new data for … ERS 2015: Landmark year for Boehringer Ingelheim's respiratory portfolio – new … |
View full post on asthma – Google News
Condition: Eosinophilic Esophagitis
Interventions: Drug: Budesonide effervescent 0.5mg tablet twice daily; Drug: Budesonide effervescent 1mg tablet twice daily; Drug: Placebo effervescent tablet twice daily
Sponsor: Dr. Falk Pharma GmbH
Not yet recruiting – verified July 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
FDA OKs New Maintenance Asthma Treatment Arnuity Ellipta
Medscape Other important safety information included in the highlights section of the prescribing information includes the following: "Arnuity Ellipta is contraindicated for primary treatment of status asthmaticus or acute episodes of asthma requiring intensive … |
View full post on asthma – Google News